艾美疫苗(06660.HK):第二代高效價吸附破傷風疫苗獲得臨牀試驗許可
格隆匯12月19日丨艾美疫苗(06660.HK)公吿,集團第二代高效價吸附破傷風疫苗已於近日獲得國家藥品監督管理局《藥物臨牀試驗批准通知書》,標誌着該疫苗的研發進入了新的階段。
破傷風是一種極為嚴重的潛在致命性疾病,目前接種破傷風疫苗是預防破傷風最經濟有效的措施。此外,集團正在積極推進吸附無細胞百白破-HIB聯合疫苗(以下簡稱"四聯疫苗")、五聯疫苗等多聯疫苗的研發。其中,四聯疫苗用於預防百日咳、白喉、破傷風和b型流感嗜血桿菌引起的侵入性感染,具有減少嬰幼兒的接種針次,增強家長和嬰幼兒接種依從性等優勢。多聯疫苗是行業的發展趨勢,根據行業顧問灼識諮詢數據,預計2030年國內市場規模約為100億元人民幣。
該疫苗的研發符合集團產品研發戰略佈局,是實現集團研發多聯多價產品的重要一步,將進一步完善集團的產品梯隊,有利於豐富集團產品線、鞏固集團行業地位,實現集團業績的持續高速增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.